Trial · NCT03026166
Results by group42
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 42
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants With Dose-limiting Toxicities (DLT) | Rovalpituzumab Tesirine and Nivolumab | 1 | Participants | ||
| Number of Participants With Dose-limiting Toxicities (DLT) | Rovalpituzumab Tesirine and Nivolumab + Ipilimumab | 3 | Participants | ||
| Number of Participants With Adverse Events (AEs) | Rovalpituzumab Tesirine and Nivolumab | Any adverse event | 30 | Participants | |
| Number of Participants With Adverse Events (AEs) | Rovalpituzumab Tesirine and Nivolumab + Ipilimumab | Any adverse event | 12 | Participants | |
| Number of Participants With Adverse Events (AEs) | Rovalpituzumab Tesirine and Nivolumab | Drug-related adverse event | 29 | Participants | |
| Number of Participants With Adverse Events (AEs) | Rovalpituzumab Tesirine and Nivolumab + Ipilimumab | Drug-related adverse event | 12 | Participants | |
| Number of Participants With Adverse Events (AEs) | Rovalpituzumab Tesirine and Nivolumab | Serious adverse event | 23 | Participants | |
| Number of Participants With Adverse Events (AEs) | Rovalpituzumab Tesirine and Nivolumab + Ipilimumab | Serious adverse event | 9 | Participants | |
| Number of Participants With Adverse Events (AEs) | Rovalpituzumab Tesirine and Nivolumab | Drug-related serious adverse event | 13 | Participants | |
| Number of Participants With Adverse Events (AEs) | Rovalpituzumab Tesirine and Nivolumab + Ipilimumab | Drug-related serious adverse event | 6 | Participants | |
| Number of Participants With Adverse Events (AEs) | Rovalpituzumab Tesirine and Nivolumab | Grade 3 adverse event | 11 | Participants | |
| Number of Participants With Adverse Events (AEs) | Rovalpituzumab Tesirine and Nivolumab + Ipilimumab | Grade 3 adverse event | 7 | Participants | |
| Number of Participants With Adverse Events (AEs) | Rovalpituzumab Tesirine and Nivolumab | Grade 4 adverse event | 1 | Participants | |
| Number of Participants With Adverse Events (AEs) | Rovalpituzumab Tesirine and Nivolumab + Ipilimumab | Grade 4 adverse event | 1 | Participants | |
| Number of Participants With Adverse Events (AEs) | Rovalpituzumab Tesirine and Nivolumab | Grade 5 adverse event | 14 | Participants | |
| Number of Participants With Adverse Events (AEs) | Rovalpituzumab Tesirine and Nivolumab + Ipilimumab | Grade 5 adverse event | 4 | Participants | |
| Number of Participants With Adverse Events (AEs) | Rovalpituzumab Tesirine and Nivolumab | Drug-related Grade 3 adverse event | 9 | Participants | |
| Number of Participants With Adverse Events (AEs) | Rovalpituzumab Tesirine and Nivolumab + Ipilimumab | Drug-related Grade 3 adverse event | 10 | Participants | |
| Number of Participants With Adverse Events (AEs) | Rovalpituzumab Tesirine and Nivolumab | Drug-related Grade 4 adverse event | 3 | Participants | |
| Number of Participants With Adverse Events (AEs) | Rovalpituzumab Tesirine and Nivolumab + Ipilimumab | Drug-related Grade 4 adverse event | 1 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03026166/results